Resalis Therapeutics
Resalis Therapeutics develops RNA-based therapeutics for metabolic diseases, focusing on its lead program RES-010 for obesity. RES-010 targets miR-22 to provide longer-lasting weight reduction and improve the durability of existing therapies. The company leverages its understanding of non-coding RNA and lipid metabolism to create safe and effective treatments.
Buy Funded Startups lists
Funding Round: Series A
Funding Amount: €10M
Date: 04-Jan-2024
Investors: Sunstone Life Science Ventures, Claris Ventures, angel investors
Markets: Biotechnology, Pharmaceuticals, Healthtech, Biotechnology Research, Clinical Trials, Health Care, Medical, Product Research, Therapeutics
HQ: Turin, Piedmont, Italy
Founded: 2021
Website: https://www.resalistherapeutics.com/
LinkedIn: https://www.linkedin.com/company/resalistherapeutics/
Crunchbase: https://www.crunchbase.com/organization/resalis-therapeutics
Leave a Comment
Comments
No comments yet.